summary

UCLA Health - Can a Kidney Tumor Come Back after Treatment | UCLA Health | Brian Shuch, MD

Thumbnail of the video “UCLA Health - Can a Kidney Tumor Come Back after Treatment | UCLA Health | Brian Shuch, MD”
Community upload. AI output has not been independently verified.

Short Summary

Main recommendation: Follow your recommended surveillance imaging schedule after treatment, because kidney tumor recurrence can occur months or years later and early imaging is the key to catching it sooner. Higher-risk patients, especially those with clear cell kidney cancer, may also be offered adjuvant therapy to lower recurrence risk.

Key Points

  • Residual tumor cells left after partial nephrectomy (at the edge of the removed tumor) or after ablation (where freezing or burning did not reach the critical temperature) can regrow at the original site, which is a local recurrence.
  • According to Dr. Shuch, a new tumor in either kidney, unrelated to the prior diagnosis, is called a de novo occurrence due to multifocality, and he estimates this occurs in about 2 to 10% of patients.
  • Distant recurrence happens when cells enter the bloodstream before surgery and hide as microscopic deposits that later grow; kidney cancer commonly spreads to lymph nodes, lung, liver, brain, and bone.
  • Recurrence risk is estimated from tumor size, cancer type, grade (how aggressive it looks), and stage, which guides individualized surveillance.
  • Adjuvant therapy after nephrectomy, including oral and intravenous agents, is offered to highest-risk clear cell patients, and UCLA has clinical trials and FDA-approved options.

Details Worth Noting

  • Concrete instructions: Stay on the surveillance approach recommended by your surgeon, radiation oncologist, or interventional radiologist after ablation. Ask for a clear understanding of how closely you will be followed and which imaging modalities will be used, so you stay on course and can find a recurrence earlier.
  • The speaker states that a less aggressive tumor may recur years later, while a more aggressive tumor may recur more quickly, so timing depends on biology.
  • Invasion can occur into adjacent organs or through the kidney's medulla or parenchyma, and complete removal of the tumor may reduce this risk.
  • Invisible metastases may grow over time before becoming detectable on imaging, which is why a surgeon cannot say a patient is definitively cured.
  • Adjuvant therapy is described as given after nephrectomy and is aimed at lowering recurrence risk and improving outcomes; urologists and medical oncologists at UCLA often work together to deliver these treatments.

Bottom Line

Recurrence after kidney tumor treatment is possible and can be local, new, or distant, so consistent imaging follow-up matters most for catching it early, and higher-risk patients may have additional therapy options.